Safety, Tolerability, and Immunogenicity of a SARS-CoV-2 Recombinant Spike RBD Protein Vaccine: A Randomised, Double-Blind, Placebo-Controlled, Phase 1-2 Clinical Trial (ABDALA Study)

Francisco Hernández‐Bernal, Verena L. Muzio‐González, Yenima Martín‐Bauta et al.|SSRN Electronic Journal|2022

Cited by 5